Menú Cerrar

Denosumab for Dialysis Patients With Osteoporosis: A Cohort Study

Kyohei Kunizawa 1 2Rikako Hiramatsu 1Junichi Hoshino 3 4 5Hiroki Mizuno 6Yuko Ozawa 6Akinari Sekine 6Masahiro Kawada 6Keiichi Sumida 1Eiko Hasegawa 6Masayuki Yamanouchi 1Noriko Hayami 1Tatsuya Suwabe 1Naoki Sawa 1Yoshifumi Ubara 1 7Kenmei Takaichi 1 6 7

 DOI: 10.1038/s41598-020-59143-8


Evidence for the efficacy of denosumab in HD patients is limited. Accordingly, here we report a study on the safety and efficacy of denosumab in these patients. We prospectively followed 324 patients (121 HD and 203 non-HD patients) receiving denosumab between June 2013 and May 2018, assessing changes in bone mineral density (BMD) and bone metabolic markers, and noting side-effects. Annual changes in BMD at the lumbar spine in HD and non-HD patients from baseline were, respectively, 6.7 ± 11.1% and 7.5 ± 10.2% (p = 0.60), those at the femoral neck were 4.3 ± 7.9% and 3.1 ± 9.5% (p = 0.32), and those at the distal radius were -0.5 ± 6.4% and 0.2 ± 13.0% (p = 0.66). The prevalence of hypocalcemia (<8.5 mg/dL) was significantly higher in HD than in non-HD patients (35.6% vs 5.4%, p < 0.001). The median elapsed time between the first injection of denosumab and the occurrence of hypocalcemia was 7 days in HD patients. The decrease of serum calcium was greater in patients with higher TRACP5b, corticosteroid use, and those without CaCO3 supplementation. Our study suggests that denosumab was equally as effective in HD as non-HD patients. However, careful hypocalcemia monitoring, for at least 4 weeks, is recommended for HD patients.